Implantable cardioverter-defibrillator (ICD) therapy is clearly an effective therapy for selected patients in definable populations. The benefits and risks of ICD therapy are directly impacted by programming and surgical decisions. This flexibility is both a great strength and a weakness, for which there has been no prior official discussion or guidance. This consensus statement provides a state of the art review of the field and reports the recommendations of a writing group comprised of international experts. The consensus statement includes 32 distinctive recommendations which were approved by an average of 96 percent of the 35 writing committee members.
Learn how to implement more than 30 recommendations from the document in your clinical practice by viewing this activity, presented by the document Chairs.